ELDN NASDAQ
Eledon Pharmaceuticals, Inc.
1W: -1.5%
1M: -2.5%
3M: +77.6%
YTD: +140.1%
1Y: +27.1%
3Y: +76.0%
5Y: -56.0%
$3.89
+0.00 (+0.00%)
Weekly Expected Move ±8.6%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (21)
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Target Price from Brokerages
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Target Price from Brokerages
Q1 Earnings Estimate for ELDN Issued By Noble Financial
Eledon Pharmaceuticals GAAP EPS of -$0.52 beats by $0.15
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
Eledon Pharma rises on FDA orphan status for lead asset
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
Brokerages Set Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Target Price at $9.67
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Price Target from Analysts
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Analysts Set Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Target Price at $9.67
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference